Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many claims are marked as absent from the provided label content (notably multiple indication/outcome claims and several mechanism/onset claims). While several safety statements are supported, the overall set is not consistent with the supplied FDA-label text; key label elements like contraindications/boxed warnings/dosing were not evidenced for adherence.
Category Scores
Accurate Statements
Methylprednisolone is a synthetic corticosteroid.
Supported in provided label excerpt under ACTIONS (synthetic analogs used for potent anti-inflammatory effects).
Methylprednisolone suppresses the immune system.
Supported in WARNINGS (corticosteroids suppress the immune system and increase infection risk).
Methylprednisolone reduces inflammation.
Supported in ACTIONS (synthetic analogs primarily used for potent anti-inflammatory effects).
Methylprednisolone can cause weight gain.
Partially supported by label WARNINGS/ADVERSE REACTIONS references to metabolic effects including fluid/salt retention and hypertension/volume effects (weight gain not explicitly quoted in provided text, but partially supported per assessment).
Methylprednisolone can cause weight gain due to increased appetite and water retention.
Partially supported by label WARNINGS/ADVERSE REACTIONS via water/salt retention and fluid retention; increased appetite component not explicitly supported in provided excerpts (partial support per assessment).
Methylprednisolone can increase the risk of infections.
Supported in WARNINGS (increase risk of infection with any pathogen; infection complications increase with dose).
Methylprednisolone can increase the risk of tuberculosis.
Supported in WARNINGS->Tuberculosis (reactivation may occur; monitor; chemoprophylaxis during prolonged therapy).
Long-term use of methylprednisolone can lead to osteoporosis.
Supported in ADVERSE REACTIONS->Musculoskeletal (Osteoporosis).
Long-term use of methylprednisolone can increase the risk of glaucoma.
Supported in WARNINGS->Ophthalmic Effects and/or ADVERSE REACTIONS->Ophthalmic effects (glaucoma/increased intraocular pressure).
Long-term use of methylprednisolone can increase blood pressure, leading to hypertension.
Supported in WARNINGS->Hypertension, Volume Overload, and Hypokalemia and ADVERSE REACTIONS->Fluid and Electrolyte Disturbances (Hypertension; fluid/volume effects; potassium loss).
Unsupported Statements
Methylprednisolone mimics the effects of cortisol.
Not supported by provided label excerpts (flagged absent from label in provided assessment).
Methylprednisolone is used to treat asthma.
Not supported by provided label excerpted INDICATIONS AND USAGE content (flagged absent from label).
Methylprednisolone is used to treat severe asthma attacks.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone is used to prevent asthma exacerbations.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone is used to treat rheumatoid arthritis.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone reduces inflammation in rheumatoid arthritis.
Disease-specific anti-inflammatory claim not supported in provided label excerpts (flagged absent from label).
Methylprednisolone slows disease progression in patients with rheumatoid arthritis.
Disease-modifying/progression-slowing claim not supported in provided label excerpts (flagged absent from label).
Methylprednisolone is used to treat lupus.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone is used to treat lupus nephritis.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone is used to treat multiple sclerosis.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone is used to treat acute exacerbations of multiple sclerosis.
Not supported by provided label excerpts (flagged absent from label).
Methylprednisolone prevents the release of chemical messengers that trigger allergic reactions.
Mechanism claim not supported by provided label excerpts (flagged absent from label).
Methylprednisolone provides rapid relief from inflammation.
Onset/rapidity claim not supported by provided label excerpts (flagged absent from label).
Methylprednisolone improves lung function in patients with asthma and other respiratory conditions.
Outcome/efficacy claim not supported by provided label excerpts (flagged absent from label).
Methylprednisolone reduces disease activity in patients with rheumatoid arthritis.
Outcome/disease-activity claim not supported by provided label excerpts (flagged absent from label).
Methylprednisolone reduces disease activity in patients with lupus.
Outcome/disease-activity claim not supported by provided label excerpts (flagged absent from label).
Methylprednisolone can cause mood changes including anxiety, depression, and irritability.
Neuropsychiatric adverse effect list in provided excerpts does not support anxiety/depression/irritability specifically (flagged absent from label in provided assessment).
Methylprednisolone can increase the risk of pneumonia.
Provided assessment marked only partial support; based on provided label excerpts, pneumonia is not explicitly confirmed.
The patent for methylprednisolone (Medrol) expired in 1997.
Patent/market commentary not present in provided label excerpts (flagged absent from label).
Generic versions of methylprednisolone are still available.
Market availability/patent commentary not present in provided label excerpts (flagged absent from label).
The patent for the injectable form of methylprednisolone (Solu-Medrol) expired in 2018.
Patent/market commentary not present in provided label excerpts (flagged absent from label).
Methylprednisolone provides rapid relief from inflammation.
Duplicate of earlier rapid-onset claim; not supported by provided label excerpts.
Contradictions
Important Omissions
FDA-label compliant dosing/administration details (e.g., initial dosage range, maintenance titration, stopping/withdrawal instructions).
Importance:
High
Contraindications statement (systemic fungal infections and known hypersensitivity).
Importance:
High
Boxed warning status/review (none mentioned/assessed in the provided claim set).
Importance:
Moderate
Specific population labeling beyond the provided excerpts (e.g., pregnancy/nursing guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple efficacy/indication claims were not supported by the supplied label excerpts, which could mislead use. Some safety statements (immunosuppression/infection risk, TB reactivation risk, osteoporosis/glaucoma/hypertension) were supported, but key label elements (contraindications, dosing/withdrawal guidance) were not demonstrated in the claim set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Numerous indications, disease-specific effects, and mechanism/rapidity/outcome claims are not supported by the provided FDA-label excerpts.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label text (e.g., anti-inflammatory/suppresses immune system, infection/TB monitoring risks, specific adverse reactions listed) and incorporate label-required elements such as contraindications, dosing/administration, and population guidance when making safety use statements.